Compare Quest Diagnostics Inc (DGX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vital Farms Inc — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while Vital Farms Inc trades at $13.03 (market cap $561.10M). The key difference: Quest Diagnostics Inc is far larger — about 40.6× Vital Farms Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| DGX | VITL | |
|---|---|---|
Market Cap | $22.80B | $561.10M |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $52.41 |
52-Week Low | $166.42 | $8.28 |
Enterprise Value | $28.82B | $563.90M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Vital Farms (VITL) trades at $12.78, down 1.31% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 15.44% ROE and attractive valuation ratios (P/E 12.59, P/S 0.76). Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while revenue grew to $759M in 2025. The stock faces headwinds from multiple class action lawsuits filed in May 2026, creating investor uncertainty despite analyst consensus favoring a buy rating.
The outlook remains cautiously optimistic with a $13.50 consensus price target offering 5.6% upside potential. Key opportunities include sustained profitability and market positioning in natural foods, while risks center on legal challenges and projected earnings volatility. Institutional sentiment leans bullish with no sell ratings, but negative cash flow trends require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
